Laurus Labs

{
  "main_header": {
    "sid": 1002699,
    "name": "Laurus Labs",
    "stock_name": "Laurus Labs",
    "full_name": "Laurus Labs Ltd",
    "name_url": "stocks-analysis/laurus-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "980.10",
    "chg": 26.2,
    "chgp": "2.75%",
    "dir": 1,
    "prev_price": "953.90",
    "mcapval": "53,311.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 540222,
    "symbol": "LAURUSLABS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE947Q01028",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "19.65 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/laurus-labs-1002699-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "text": "Part of MojoOne Strategy",
      "type": "RP",
      "url": "https://www.marketsmojo.com/mojopro/strategy/3",
      "ismore": 0,
      "all_data": [],
      "is_blur": 1,
      "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/laurus-labs-1002699-0&utm_source=Spage_Score_PartofStrategies"
    }
  },
  "news": {
    "results": [
      {
        "title": "Laurus Labs Ltd Opens Strong with Significant Gap Up on 3 Feb 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/laurus-labs-ltd-opens-strong-with-significant-gap-up-on-3-feb-2026-3817942",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/LaurusLabsLtd_gapup_3817942.png",
        "date": "2026-02-03 09:57:24",
        "description": "Laurus Labs Ltd commenced trading on 3 Feb 2026 with a notable gap up, opening 5.36% higher than its previous close, signalling robust positive sentiment in the Pharmaceuticals & Biotechnology sector. The stock outperformed both its sector and the broader Sensex index, continuing its recent upward momentum."
      },
      {
        "title": "Laurus Labs Ltd is Rated Buy by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/laurus-labs-ltd-is-rated-buy-by-marketsmojo-3812421",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/LaurusLabsLtd_mojoScore_3812421.png",
        "date": "2026-01-31 10:10:48",
        "description": "Laurus Labs Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 09 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with an up-to-date perspective on its performance and outlook."
      },
      {
        "title": "Laurus Labs Ltd Reports Outstanding Quarterly Financial Performance Amid Strong Long-Term Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/laurus-labs-ltd-reports-outstanding-quarterly-financial-performance-amid-strong-long-term-returns-3804860",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/LaurusLabsLtd_fintrenddot_3804860.png",
        "date": "2026-01-27 08:00:20",
        "description": "Laurus Labs Ltd has delivered an outstanding quarterly performance for the December 2025 quarter, prompting an upgrade in its financial trend rating from very positive to outstanding. The pharmaceutical and biotechnology company posted record-high revenues and profitability metrics, signalling robust operational efficiency and financial health amid a challenging market environment."
      },
      {
        "title": "Laurus Labs Declines 5.50%: 5 Key Factors Shaping This Week’s Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/laurus-labs-declines-550-5-key-factors-shaping-this-weeks-volatility-3803315",
        "imagepath": "",
        "date": "2026-01-24 13:04:14",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Jan 19:</strong> Stock opens at Rs.1,062.50 amid market weakness</p>\n                    <p><strong>Jan 20:</strong> Sharp open interest surge despite price decline</p>\n                    <p><strong>Jan 21:</strong> Intraday low hit at Rs.983.90 amid price pressure</p>\n                    <p><strong>Jan 23:</strong> Significant gap up opens at +5.47%, followed by Q3 FY26 earnings report</p>\n                    <p><strong>Jan 23:</strong> Week closes at Rs.1,017.15 (-5.50%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,076.35</div></div>\n            ..."
      },
      {
        "title": "Are Laurus Labs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-laurus-labs-ltd-latest-results-good-or-bad-3802448",
        "imagepath": "",
        "date": "2026-01-23 19:16:31",
        "description": "Laurus Labs Ltd's latest financial results for Q3 FY26 reflect a significant operational turnaround, characterized by strong growth in both net sales and net profit. The company reported net sales of ₹1,778.29 crores, representing a year-on-year growth of 25.67%, compared to ₹1,415.05 crores in the same quarter last year. This growth trajectory also includes a sequential increase of 7.55% from the previous quarter, indicating consistent demand across its core therapeutic segments.\n\nThe net profit for the quarter reached ₹251.66 crores, showcasing a remarkable year-on-year growth of 172.65% from ₹92.30 crores in Q3 FY25. Additionally, the operating margin improved to 27.00%, marking the highest level in the past eight quarters, which reflects enhanced operational efficiency and a favorable product mix. The profit after tax margin also expanded significantly to 14.23% from 6.40% in the corresponding quarter l..."
      },
      {
        "title": "Laurus Labs Q3 FY26: Stellar Turnaround with 173% Profit Surge Masks Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/laurus-labs-q3-fy26-stellar-turnaround-with-173-profit-surge-masks-valuation-concerns-3802383",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/LaurusLabs_quaterlyResult_3802383.png",
        "date": "2026-01-23 17:47:28",
        "description": "Laurus Labs Ltd., the Visakhapatnam-based pharmaceutical and biotechnology manufacturer, delivered an impressive third-quarter performance for FY2026, with consolidated net profit surging 172.65% year-on-year to ₹251.66 crores compared to ₹92.30 crores in Q3 FY25. The sequential momentum remained robust, with profits climbing 29.08% quarter-on-quarter from ₹194.97 crores in Q2 FY26. The stock, currently trading at ₹1,017.15, has gained 73.89% over the past year, substantially outperforming the broader pharmaceuticals sector which declined 2.57% during the same period."
      },
      {
        "title": "Laurus Labs Ltd Opens Strong with Significant Gap Up on 23 Jan 2026",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/laurus-labs-ltd-opens-strong-with-significant-gap-up-on-23-jan-2026-3801387",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/LaurusLabsLtd_gapup_3801387.png",
        "date": "2026-01-23 10:16:03",
        "description": "Laurus Labs Ltd commenced trading on 23 Jan 2026 with a notable gap up, opening 5.47% higher than its previous close, signalling robust positive sentiment in the Pharmaceuticals & Biotechnology sector. This strong start was accompanied by an intraday high of Rs 1059.95, underscoring sustained momentum in early trading hours."
      },
      {
        "title": "Laurus Labs Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/laurus-labs-ltd-sees-technical-momentum-shift-amid-mixed-indicator-signals-3797718",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/LaurusLabsLtd_technicaldot_3797718.png",
        "date": "2026-01-21 08:04:12",
        "description": "Laurus Labs Ltd has experienced a notable shift in its technical momentum, transitioning from a bullish to a mildly bullish trend as of January 2026. Despite a recent decline in share price, the stock continues to exhibit a complex interplay of technical indicators, reflecting both caution and underlying strength within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Laurus Labs Sees Sharp Open Interest Surge Amid Mixed Price Action",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/laurus-labs-sees-sharp-open-interest-surge-amid-mixed-price-action-3796703",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/LaurusLabsLtd_oi_spurts_by_underlying_3796703.png",
        "date": "2026-01-20 15:00:23",
        "description": "Laurus Labs Ltd (LAURUSLABS), a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.75% increase in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning despite a recent price decline. This surge in OI, coupled with volume patterns and price movements, offers valuable insights into potential directional bets and market sentiment surrounding the stock."
      }
    ],
    "total": 655,
    "sid": "1002699",
    "stock_news_url": "https://www.marketsmojo.com/news/laurus-labs-1002699"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "28-Jan-2026",
      "details": "Please see annexed enclosure.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "24-Jan-2026",
      "details": "Please see annexed enclosure.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "23-Jan-2026",
      "details": "Please see enclosed annexure",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Laurus Labs Ltd has declared <strong>40%</strong> dividend, ex-date: 31 Oct 25",
          "dt": "2025-10-31",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Laurus Labs Ltd has announced <strong>2:10</strong> stock split, ex-date: 29 Sep 20",
          "dt": "2020-09-29",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Laurus Labs Ltd Opens Strong with Significant Gap Up on 3 Feb 2026

2026-02-03 09:57:24

Laurus Labs Ltd commenced trading on 3 Feb 2026 with a notable gap up, opening 5.36% higher than its previous close, signalling robust positive sentiment in the Pharmaceuticals & Biotechnology sector. The stock outperformed both its sector and the broader Sensex index, continuing its recent upward momentum.

Read full news article

Laurus Labs Ltd is Rated Buy by MarketsMOJO

2026-01-31 10:10:48

Laurus Labs Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 09 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with an up-to-date perspective on its performance and outlook.

Read full news article

Laurus Labs Ltd Reports Outstanding Quarterly Financial Performance Amid Strong Long-Term Returns

2026-01-27 08:00:20

Laurus Labs Ltd has delivered an outstanding quarterly performance for the December 2025 quarter, prompting an upgrade in its financial trend rating from very positive to outstanding. The pharmaceutical and biotechnology company posted record-high revenues and profitability metrics, signalling robust operational efficiency and financial health amid a challenging market environment.

Read full news article

Laurus Labs Declines 5.50%: 5 Key Factors Shaping This Week’s Volatility

2026-01-24 13:04:14

Key Events This Week

Jan 19: Stock opens at Rs.1,062.50 amid market weakness

Jan 20: Sharp open interest surge despite price decline

Jan 21: Intraday low hit at Rs.983.90 amid price pressure

Jan 23: Significant gap up opens at +5.47%, followed by Q3 FY26 earnings report

Jan 23: Week closes at Rs.1,017.15 (-5.50%)

Week Open

Rs.1,076.35

...

Read full news article

Are Laurus Labs Ltd latest results good or bad?

2026-01-23 19:16:31

Laurus Labs Ltd's latest financial results for Q3 FY26 reflect a significant operational turnaround, characterized by strong growth in both net sales and net profit. The company reported net sales of ₹1,778.29 crores, representing a year-on-year growth of 25.67%, compared to ₹1,415.05 crores in the same quarter last year. This growth trajectory also includes a sequential increase of 7.55% from the previous quarter, indicating consistent demand across its core therapeutic segments. The net profit for the quarter reached ₹251.66 crores, showcasing a remarkable year-on-year growth of 172.65% from ₹92.30 crores in Q3 FY25. Additionally, the operating margin improved to 27.00%, marking the highest level in the past eight quarters, which reflects enhanced operational efficiency and a favorable product mix. The profit after tax margin also expanded significantly to 14.23% from 6.40% in the corresponding quarter l...

Read full news article

Laurus Labs Q3 FY26: Stellar Turnaround with 173% Profit Surge Masks Valuation Concerns

2026-01-23 17:47:28

Laurus Labs Ltd., the Visakhapatnam-based pharmaceutical and biotechnology manufacturer, delivered an impressive third-quarter performance for FY2026, with consolidated net profit surging 172.65% year-on-year to ₹251.66 crores compared to ₹92.30 crores in Q3 FY25. The sequential momentum remained robust, with profits climbing 29.08% quarter-on-quarter from ₹194.97 crores in Q2 FY26. The stock, currently trading at ₹1,017.15, has gained 73.89% over the past year, substantially outperforming the broader pharmaceuticals sector which declined 2.57% during the same period.

Read full news article

Laurus Labs Ltd Opens Strong with Significant Gap Up on 23 Jan 2026

2026-01-23 10:16:03

Laurus Labs Ltd commenced trading on 23 Jan 2026 with a notable gap up, opening 5.47% higher than its previous close, signalling robust positive sentiment in the Pharmaceuticals & Biotechnology sector. This strong start was accompanied by an intraday high of Rs 1059.95, underscoring sustained momentum in early trading hours.

Read full news article

Laurus Labs Ltd Sees Technical Momentum Shift Amid Mixed Indicator Signals

2026-01-21 08:04:12

Laurus Labs Ltd has experienced a notable shift in its technical momentum, transitioning from a bullish to a mildly bullish trend as of January 2026. Despite a recent decline in share price, the stock continues to exhibit a complex interplay of technical indicators, reflecting both caution and underlying strength within the Pharmaceuticals & Biotechnology sector.

Read full news article

Laurus Labs Sees Sharp Open Interest Surge Amid Mixed Price Action

2026-01-20 15:00:23

Laurus Labs Ltd (LAURUSLABS), a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 10.75% increase in open interest (OI) in its derivatives segment, signalling heightened market activity and evolving investor positioning despite a recent price decline. This surge in OI, coupled with volume patterns and price movements, offers valuable insights into potential directional bets and market sentiment surrounding the stock.

Read full news article

View All News